Jacob Thomas

430 total citations
45 papers, 279 citations indexed

About

Jacob Thomas is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jacob Thomas has authored 45 papers receiving a total of 279 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 14 papers in Molecular Biology and 13 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jacob Thomas's work include Cancer Immunotherapy and Biomarkers (14 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and CAR-T cell therapy research (7 papers). Jacob Thomas is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and CAR-T cell therapy research (7 papers). Jacob Thomas collaborates with scholars based in United States, United Kingdom and Spain. Jacob Thomas's co-authors include Fairooz F. Kabbinavar, Anthony B. El-Khoueiry, Gino K. In, Steven Daveluy, Heinz‐Josef Lenz, Alan L. Ho, Kelsey Poorman, Afsaneh Barzi, Anne Aumont and Nilofer S. Azad and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Jacob Thomas

36 papers receiving 268 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jacob Thomas United States	10	126	122	77	69	33	45	279
Qifan Yang China	10	141 1.1×	80 0.7×	100 1.3×	79 1.1×	44 1.3×	23	269
Zhitao Zong China	7	99 0.8×	102 0.8×	124 1.6×	57 0.8×	60 1.8×	8	317
Johnathan Ebben United States	8	123 1.0×	182 1.5×	30 0.4×	67 1.0×	55 1.7×	11	322
Guilong Tanzhu China	8	119 0.9×	169 1.4×	32 0.4×	87 1.3×	84 2.5×	15	349
Yuning J. Tang United States	9	94 0.7×	192 1.6×	70 0.9×	46 0.7×	83 2.5×	20	322
Luyan Mu China	12	106 0.8×	188 1.5×	83 1.1×	63 0.9×	137 4.2×	20	383
Shu‐Jyuan Chang Taiwan	12	124 1.0×	204 1.7×	51 0.7×	35 0.5×	95 2.9×	25	343
Natalie L. Lister Australia	9	148 1.2×	137 1.1×	111 1.4×	81 1.2×	45 1.4×	12	364
Jeremy S. Frieling United States	10	184 1.5×	100 0.8×	101 1.3×	76 1.1×	62 1.9×	21	327
Rhyannon Spangler United States	4	107 0.8×	175 1.4×	51 0.7×	69 1.0×	122 3.7×	4	340

Countries citing papers authored by Jacob Thomas

Since Specialization

Citations

This map shows the geographic impact of Jacob Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacob Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacob Thomas more than expected).

Fields of papers citing papers by Jacob Thomas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacob Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacob Thomas. The network helps show where Jacob Thomas may publish in the future.

Co-authorship network of co-authors of Jacob Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of Jacob Thomas. A scholar is included among the top collaborators of Jacob Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacob Thomas. Jacob Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hanna, Glenn J., Gregory M. Coté, Rashmi Chugh, et al.. (2025). Safety and Efficacy of a Selective Inhibitor of Cyclin-dependent Kinase 9 (KB-0742) in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma. Cancer Research Communications. 5(5). 767–773.

Thomas, Jacob, et al.. (2025). Real-World Incidence of Anaplastic Lymphoma Kinase Alterations in Hispanics with Non–Small Cell Lung Cancer at a Large Academic Institution in Los Angeles. Cancer Research Communications. 5(2). 277–286. 1 indexed citations

Kim, Hye Ryun, Juanita Lopez, Anthony B. El-Khoueiry, et al.. (2025). Bispecific innate cell engager (ICE) AFM24 in combination with atezolizumab in patients with advanced/metastatic EGFR -expressing non-small cell lung cancer (NSCLC) without driver mutations: Initial results from a phase 2a study.. Journal of Clinical Oncology. 43(16_suppl). 2609–2609.

Gitlitz, Barbara J., Vinay Duddalwar, Kevin G. King, et al.. (2024). Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma. Oncotarget. 15(1). 444–458.

Wong, W. Douglas, Jaspreet Singh Grewal, James Russell, et al.. (2024). 868P Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Annals of Oncology. 35. S622–S623. 3 indexed citations

Kim, Hye Ryun, Omar Saavedra, Andrés Cervantes, et al.. (2024). Preliminary results from the phase 2 study of AFM24 in combination with atezolizumab in patients with EGFR wild-type (EGFR-WT) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 2522–2522. 9 indexed citations

Brohl, Andrew S., Ann W. Silk, Jacob Thomas, et al.. (2024). Phase 1b trial of IFx-Hu2.0, a novel in situ cancer vaccine, in checkpoint inhibitor-resistant Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC).. Journal of Clinical Oncology. 42(16_suppl). 9592–9592. 1 indexed citations

Rodón, Jordi, Estelamari Rodríguez, Michael L. Maitland, et al.. (2024). A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations. ESMO Open. 9(4). 102961–102961. 21 indexed citations

Hanna, Glenn J., Douglas R. Adkins, Jacob Thomas, et al.. (2024). FIT-001: A phase 1 clinical trial of the farnesyl transferase inhibitor KO-2806 alone or as part of combination therapy for advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS4607–TPS4607.

10.

Benjamin, David J., Katherine Y. Wojcik, Alice W. Lee, et al.. (2024). Characterization of Thyroid Cancer among Hispanics in California, USA, from 2010 to 2020. Cancers. 16(6). 1101–1101.

11.

Nieva, Jorge J., et al.. (2024). Efficacy from the phase 1 study of FID-007, a novel nanoparticle paclitaxel formulation, in patients with head and neck squamous cell carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 6042–6042.

12.

Waltzman, Roger J., Diana L. Hanna, Angela Alistar, et al.. (2024). Preliminary results of a phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2583–2583. 3 indexed citations

13.

Thomas, Jacob, J. Eva Selfridge, Costantine Albany, et al.. (2024). Phase 1 study of BA3071, an anti–CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2602–2602. 1 indexed citations

14.

Brohl, Andrew S., Joseph Markowitz, Zeynep Eroglu, et al.. (2023). Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant merkel cell carcinoma and cutaneous squamous cell carcinoma.. Journal of Clinical Oncology. 41(16_suppl). 9534–9534. 6 indexed citations

15.

Meyer, Christian F., Matthew Ingham, James Hu, et al.. (2023). Intratumoral INT230-6 (cisplatin, vinblastine, shao) alone or with ipilimumab prolonged survival with favorable safety in adults with refractory sarcomas.. Journal of Clinical Oncology. 41(16_suppl). 11568–11568. 3 indexed citations

16.

El-Khoueiry, Anthony B., Juanita Lopez, Omar Saavedra, et al.. (2022). 754P A phase I/IIa dose escalation study of AFM24 in patients with epidermal growth factor receptor-expressing (EGFR) solid tumors: Results from phase I. Annals of Oncology. 33. S889–S889.

17.

Thomas, Jacob, Anthony B. El-Khoueiry, Barry J. Maurer, et al.. (2021). A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors. Cancer Chemotherapy and Pharmacology. 87(4). 525–532. 14 indexed citations

18.

Capone, Stephen, Charité Ricker, Jacob Thomas, et al.. (2021). A Case Series of Multiple Primary Malignancies Among Patients With Advanced Melanoma. Cureus. 13(6). e15480–e15480. 2 indexed citations

19.

In, Gino K., Jacob Thomas, & Ann W. Silk. (2021). Cutaneous Malignancies of the Head and Neck. Hematology/Oncology Clinics of North America. 35(5). 991–1008. 1 indexed citations

20.

Kosaraju, Jayasankar, Laura K. Hamilton, Anne Aumont, et al.. (2020). Dysregulated expression of monoacylglycerol lipase is a marker for anti-diabetic drug metformin-targeted therapy to correct impaired neurogenesis and spatial memory in Alzheimer's disease. Theranostics. 10(14). 6337–6360. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact